INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia

被引：0
|
作者：
Passamonti, Francesco [1 ]
Rumi, Elisa [1 ]
Della Porta, Matteo G. [1 ]
Portolan, Monica [1 ]
Elena, Chiara [1 ]
Arcaini, Luca [1 ]
Pascutto, Cristiana [1 ]
Vanelli, Laura [1 ]
Vaddi, Kris [2 ]
Lazzarino, Mario [1 ]
Cazzola, Mario [1 ]
机构：
[1] Univ Pavia, Dept Hematol Oncol, Fdn IRCCS Policlin San Matteo, I-27100 Pavia, Italy
[2] Incyte Corp, Wilmington, DE USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1135 / 1135
页数：1
相关论文
共 50 条
  • [1] Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter J.
    Levy, Richard
    Bradley, Edward
    Garrett, William
    Vaddi, Kris
    Contel, Nancy
    Sandor, Victor
    Huber, Reid Michael
    Schacter, Lee P.
    Rumi, Elisa
    Gattoni, Elisabetta
    Antonioli, Elisabetta
    Pieri, Lisa
    Cazzola, Mario
    Kantarjian, Hagop
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    BLOOD, 2010, 116 (21) : 142 - 143
  • [2] A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter
    Levy, Richard
    Bradley, Edward C.
    Schacter, Lee
    Garrett, William M.
    Vaddi, Kris
    Contel, Nancy
    Rumi, Elisa
    Gattoni, Elisabetta
    Cazzola, Mario
    Kantarjian, Hagop
    Barbui, Tiziano
    Vannucchi, Alessandro
    BLOOD, 2009, 114 (22) : 132 - 132
  • [3] Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
    Verstovsek, Srdan
    Kantarjian, Hagop
    Mesa, Ruben A.
    Pardanani, Animesh D.
    Cortes-Franco, Jorge
    Thomas, Deborah A.
    Estrov, Zeev
    Fridman, Jordan S.
    Bradley, Edward C.
    Erickson-Viitanen, Susan
    Vaddi, Kris
    Levy, Richard
    Tefferi, Ayalew
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12): : 1117 - 1127
  • [4] Discovery of INCB018424: A potent and selective JAK1/JAK2 inhibitor for the treatment of myeloproliferative neoplasms
    Rodgers, James D.
    Fridman, Jordan S.
    Shepard, S.
    Maduskuie, T. P.
    Arvanitis, A. G.
    Wang, H.
    Shao, L.
    Folmer, B.
    Falahatpisheh, N.
    Rafalski, M.
    Storace, L.
    Jalluri, R. K.
    Vaddi, K.
    Haley, P. J.
    Burn, T. C.
    Rupar, M.
    Liu, P. C.
    Covington, M. B.
    Caulder, E.
    Li, J.
    Waeltz, P.
    Margulis, A.
    Wynn, R.
    Becker-Pasha, M.
    Li, Y.
    Lo, Y.
    Thomas, B.
    Hollis, G.
    Favata, M. F.
    Wen, X.
    Kelly, J.
    Solomon, K.
    Scherle, P. A.
    Shi, J.
    Yeleswaram, S.
    Newton, R. C.
    Friedman, S. M.
    Metcalf, B.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [5] Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia
    Guglielmelli, Paola
    Pieri, Lisa
    Tagliarico, Enrico
    Zini, Roberta
    Norfo, Ruggiero
    Bosi, Alberto
    Vaddi, Kris
    Burn, Timothy
    Contel, Nancy
    Verstovsek, Srdan
    Manfredini, Rossella
    Vannucchi, Alessandro M.
    BLOOD, 2011, 118 (21) : 1646 - 1647
  • [6] A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
    Verstovsek, Srdan
    Courby, Stephane
    Griesshammer, Martin
    Mesa, Ruben A.
    Brachmann, Carrie Baker
    Kawashima, Jun
    Maltzman, Julia D.
    Shao, Lixin
    Xin, Yan
    Huang, Daniel
    Bajel, Ashish
    LEUKEMIA RESEARCH, 2017, 60 : 11 - 17
  • [7] Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders
    Fridman, Jordan
    Nussenzveig, Roberto
    Liu, Phillip
    Rodgers, James
    Burn, Timothy
    Haley, Patrick
    Scherle, Peggy
    Newton, Robert
    Hollis, Gregory
    Friedman, Steven
    Verstovsek, Srdan
    Vaddi, Kris
    BLOOD, 2007, 110 (11) : 1035A - 1036A
  • [8] Leukocyte alkaline phosphatase expression predicts the JAK2 V617F mutation status in polycythemia vera and essential thrombocythemia
    Rambaldi, A.
    Guerini, V.
    Carobbio, A.
    Salvi, A.
    Spinelli, O.
    Delaini, F.
    Finazzi, G.
    Barbui, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 414 - 415
  • [9] Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
    Quintas-Cardama, Alfonso
    Vaddi, Kris
    Liu, Phillip
    Manshouri, Taghi
    Li, Jun
    Scherle, Peggy A.
    Caulder, Eian
    Wen, Xiaoming
    Li, Yanlong
    Waeltz, Paul
    Rupar, Mark
    Burn, Timothy
    Lo, Yvonne
    Kelley, Jennifer
    Covington, Maryanne
    Shepard, Stacey
    Rodgers, James D.
    Haley, Patrick
    Kantarjian, Hagop
    Fridman, Jordan S.
    Verstovsek, Srdan
    BLOOD, 2010, 115 (15) : 3109 - 3117
  • [10] INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF)
    Mesa, Ruben A.
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Pardanani, Animesh D.
    Friedman, Steven
    Newton, Robert
    Erickson-Viitanen, Susan
    Hunter, Deborah
    Redman, John
    Yeleswaram, Swamy
    Bradley, Edward
    Tefferi, Ayalew
    BLOOD, 2008, 112 (11) : 621 - 622
12345